| Literature DB >> 34049881 |
So-Hee Hong1, Hanseul Oh2, Yong Wook Park3, Hye Won Kwak1, Eun Young Oh4, Hyo-Jung Park1, Kyung Won Kang4, Green Kim2, Bon-Sang Koo2, Eun-Ha Hwang2, Seung Ho Baek2, Hyeong-Jun Park1, Yu-Sun Lee1, Yoo-Jin Bang1, Jae-Yong Kim1, Seo-Hyeon Bae1, Su Jeen Lee3, Ki-Weon Seo3, Hak Kim3, Taewoo Kwon3, Ji-Hwan Kim3, Seonghwan Lee3, Eunsom Kim3, Yeonhwa Kim4, Jae-Hak Park5, Sang-In Park6, Marta Gonçalves7, Byung Mook Weon7, Haengdueng Jeong8, Ki Taek Nam8, Kyung-Ah Hwang9, Jihye Kim10, Hun Kim3, Sang-Myeong Lee11, Jung Joo Hong12, Jae-Hwan Nam13.
Abstract
Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), various vaccines are being developed, with most vaccine candidates focusing on the viral spike protein. Here, we developed a previously unknown subunit vaccine comprising the receptor binding domain (RBD) of the spike protein fused with the tetanus toxoid epitope P2 (RBD-P2) and tested its efficacy in rodents and nonhuman primates (NHPs). We also investigated whether the SARS-CoV-2 nucleocapsid protein (N) could increase vaccine efficacy. Immunization with N and RBD-P2 (RBDP2/N) + alum increased T cell responses in mice and neutralizing antibody levels in rats compared with those obtained using RBD-P2 + alum. Furthermore, in NHPs, RBD-P2/N + alum induced slightly faster SARS-CoV-2 clearance than that induced by RBD-P2 + alum, albeit without statistical significance. Our study supports further development of RBD-P2 as a vaccine candidate against SARS-CoV-2. Also, it provides insights regarding the use of N in protein-based vaccines against SARS-CoV-2.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34049881 DOI： 10.1126/sciadv.abg7156
Source DB: PubMed Journal: Sci Adv ISSN： 2375-2548 Impact factor: 14.136